Rethinking the effectiveness of hypomethylating agents in myelodysplastic syndromes: the 50%-2-year wall

Key Points

• To assess the effectiveness of hypomethylating agents in treating myelodysplastic syndromes and identify barriers to treatment success.
• Review of existing literature on hypomethylating agents
• Analysis of treatment outcomes in myelodysplastic syndromes
• Evaluation of resistance mechanisms
• Hypomethylating agents show variable response rates in myelodysplastic syndromes
• Approximately 50% of patients achieve a response within two years
• Treatment resistance presents significant challenges affecting long-term outcomes